Axinn Obtains Denial of a TRO Motion for Client Zydus
April 23, 2015
Axinn attorneys succeeded in obtaining a denial of a TRO motion that had sought an order to keep Axinn client Zydus from marketing its generic version of Abilify (aripiprazole). Abilify is a multi-billion dollar drug marketed by Otsuka, and Otsuka sought a ruling from the United States District Court for the District of New Jersey that the marketing of Zydus’ generic aripiprazole product would infringe Otsuka’s patent. The Axinn team included Jason Murata. Additionally, the firm was joined by a number of other defendants in opposing Otsuka’s TRO motion.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ITCTLA Mock Hearing Program 2025
Speaking Engagement
Intellectual Property
IBA Annual Conference 2025
Speaking Engagement
Antitrust
GCR Live: Global Merger Control 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
Shifting Trends in Healthcare Antitrust Enforcement: Navigating the Evolving Landscape
Axinn Viewpoints
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
In Fashion, One Day You’re In and the Next Day You’re Out (Of Chances to Plead Violations of the Sherman Act)
Axinn Viewpoints
Antitrust